News | December 25, 2025
Tanabe Pharma America transfers RADICAVA business to Shionogi
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
NUFYMCO BLA has been approved by the USFDA
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
The expansion includes a larger technical and service team and increased local procurement
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
